Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME<sup>®</sup> trial.

J Diabetes Investig · 2019 · PMC6497612 · PMID 30412655

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Notably, East Asian patients might be at particularly increased risk; in our analyses, we were limited by a relatively small subgroup, but the results showed a trend towards consistent results with the overall group.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.